CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 618 enrolled
Drug / intervention
nephrectomyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04309617
NCT04309617N/ACompleted

Provider Referral Patterns Following Nephrectomy in High-Risk Locoregional Renal Cell Carcinoma

Pfizer·observational·Posted Mar 16, 2020·Updated May 19, 2021

In Brief

An observational study evaluating nephrectomy for Renal Cell Carcinoma. Completed, enrolled 618 participants across 1 site.

Detailed Summary

This study aims at estimating the proportion of patients diagnosed with locoregional renal cell carcinoma who are at high risk for recurrence following nephrectomy, describe referral patterns, and characterize treatment in this population. Outcomes including estimation of the incidence of recurrence and disease-free interval following nephrectomy will be reported overall and among the subgroup off patients receiving adjuvant systemic therapy with sunitinib following nephrectomy.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMar 16, 2020
Enrollment StartJul 31, 2019
Primary CompletionApr 28, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.3 years ago

Interventions

nephrectomyprocedure

Surgery performed within the study period